Conversion from calcineurin inhibitors to Sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinoma

Hospices Civils de Lyon, Hôspital Edouard Herriot, Clinique Dermatologique (Pav. R), 69437 Lyon Cedex 03, France.
Anticancer research (Impact Factor: 1.83). 07/2009; 29(6):1927-32.
Source: PubMed


Immunosuppression favors the development of skin cancer. Experimental data suggest that sirolimus (SRL) has antitumoral and antiangiogenic properties. An investigation was undertaken into the effects of SRL on squamous cell carcinoma (SCC) developing in organ transplant recipients (OTR) receiving immunosuppressive treatments, with special emphasis on vascularization.
SCC that developed in eight OTR before and after conversion from calcineurin inhibitors (CNI) to SRL were compared for thickness, differentiation, ulceration, perineural invasion, density of peritumoral infiltrate, peritumoral vascularization, density of T-regulatory cells and of intratumoral Langerhans cells and growth fraction.
SCC developing under SRL showed lower peritumoral vascularization and thickness, and higher growth fraction and density of peritumoral T-regulatory cells.
Conversion from CNI to SRL at clinically relevant doses is associated in vivo with a reduced vascularization and thickness of post-transplant human cutaneous SCC. This effect could account for the beneficial effect of SRL on immunosuppression-induced skin carcinogenesis in humans.

Download full-text


Available from: Jean Kanitakis, Mar 19, 2015
17 Reads
  • Source
    • "ese drugs exhibit antitumour activity via their inhibition of angiogenesis as well as cell cycle progression and growth. Rival-Tringali et al. demonstrated that switching from a CNI to sirolimus reduced vascularization and thickness of posttransplant human cutaneous SCC in vivo [22]. Following a recent meeting of pan- European dermatology experts, transplant physicians are being recommended to have recipients switched to these more protective, antineoplastic medications, particularly in patients with documented SCC [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Solid organ transplant recipients are predisposed to actinic keratoses (AK) and nonmelanoma skin cancers, owing to the lifelong immunosuppression required. Today, increasing numbers of organ transplants are being performed and organ transplant recipients (OTRs) are surviving much longer. Photodynamic therapy (PDT) is proving a highly effective treatment modality for AK amongst this susceptible group of patients. Following an overview of the pathogenesis of AK amongst OTRs, the authors review current safety and efficacy data and how this relates to the role of PDT for the treatment of AK in OTRs.
    03/2013; 2013:349526. DOI:10.1155/2013/349526
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Indications:Graft rejection prophylaxis in 14 patients who underwent heart transplantation, and for the treatment of immunosuppressant-induced non-melanoma skin cancers (squamous cell carcinoma [SCC], basal cell carcinoma [BCC], Bowen's disease, actinic keratosis; 5 with verrucous lesions) in these 14 patients and other malignancies (1 prostate, 1 lung/prostate and 2 bladder) in 6 patients. Coexisting disease was seborrheic dermatitis in 1 patient.
    Transplant International 11/2009; 23(8):855-7. DOI:10.1111/j.1432-2277.2009.01010.x · 2.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous squamous cell carcinoma is an increasing public health concern, representing the second most common cancer in the United States. High-risk cutaneous squamous cell carcinoma represents a subgroup of this disease, where patients are at higher risk of metastasis and death. To date, there are no accepted criteria for defining or managing these patients. This review discusses the current state of knowledge of high-risk cutaneous squamous cell carcinoma and outlines reasonable management strategies based on available data.
    Journal of Clinical and Aesthetic Dermatology 04/2010; 3(4):39-48.
Show more